273 related articles for article (PubMed ID: 30043511)
1. A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.
Biliouris K; Gaitonde P; Yin W; Norris DA; Wang Y; Henry S; Fey R; Nestorov I; Schmidt S; Rogge M; Lesko LJ; Trame MN
CPT Pharmacometrics Syst Pharmacol; 2018 Sep; 7(9):581-592. PubMed ID: 30043511
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
Luu KT; Norris DA; Gunawan R; Henry S; Geary R; Wang Y
J Clin Pharmacol; 2017 Aug; 57(8):1031-1041. PubMed ID: 28369979
[TBL] [Abstract][Full Text] [Related]
3. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model.
MacCannell D; Berger Z; Kirschner J; Mercuri E; Farrar MA; Iannaccone ST; Kuntz NL; Finkel RS; Valente M; Muntoni F
CNS Drugs; 2022 Feb; 36(2):181-190. PubMed ID: 35080757
[TBL] [Abstract][Full Text] [Related]
4. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Monine M; Norris D; Wang Y; Nestorov I
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
[TBL] [Abstract][Full Text] [Related]
5. Nusinersen: First Global Approval.
Hoy SM
Drugs; 2017 Mar; 77(4):473-479. PubMed ID: 28229309
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
[TBL] [Abstract][Full Text] [Related]
7. Nusinersen: A Treatment for Spinal Muscular Atrophy.
Claborn MK; Stevens DL; Walker CK; Gildon BL
Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates.
Rigo F; Chun SJ; Norris DA; Hung G; Lee S; Matson J; Fey RA; Gaus H; Hua Y; Grundy JS; Krainer AR; Henry SP; Bennett CF
J Pharmacol Exp Ther; 2014 Jul; 350(1):46-55. PubMed ID: 24784568
[TBL] [Abstract][Full Text] [Related]
9. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
Paton DM
Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
[TBL] [Abstract][Full Text] [Related]
11. Nusinersen for the treatment of spinal muscular atrophy.
Chiriboga CA
Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
[TBL] [Abstract][Full Text] [Related]
12. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
Dutta D; Chandra G; Mohanakumar KP
J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
[TBL] [Abstract][Full Text] [Related]
13. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.
Meylemans A; De Bleecker J
Acta Neurol Belg; 2019 Dec; 119(4):523-533. PubMed ID: 31388901
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza
Ohmura T; Saeki S; Ogiwara K; Tobita K; Ling Y; Torii S
Nihon Yakurigaku Zasshi; 2018; 152(3):147-159. PubMed ID: 30185733
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.
Li Q
Yonsei Med J; 2020 Apr; 61(4):273-283. PubMed ID: 32233169
[TBL] [Abstract][Full Text] [Related]
16. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
Gidaro T; Servais L
Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
[TBL] [Abstract][Full Text] [Related]
17. Nusinersen in the Treatment of Spinal Muscular Atrophy.
Goodkey K; Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
[TBL] [Abstract][Full Text] [Related]
18. Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen.
Garofalo M; Bonanno S; Marcuzzo S; Pandini C; Scarian E; Dragoni F; Di Gerlando R; Bordoni M; Parravicini S; Gellera C; Masson R; Dosi C; Zanin R; Pansarasa O; Cereda C; Berardinelli A; Gagliardi S
Biol Direct; 2023 Sep; 18(1):57. PubMed ID: 37705059
[TBL] [Abstract][Full Text] [Related]
19. [Nusinersen in the treatment of spinal muscular atrophy].
Sinkó G; Kiss Z; Kalman B
Ideggyogy Sz; 2018 Mar; 71(3-04):90-94. PubMed ID: 29889467
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy.
Orbach R; Sagi L; Sadot E; Tokatly Latzer I; Shtamler A; Zisberg T; Fattal-Valevski A
Muscle Nerve; 2022 Dec; 66(6):762-766. PubMed ID: 36214191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
